GLP-1 Market Projected to Reach $95.3B by 2035
Question
GLP-1 Market Projected to Reach $95.3B by 2035
Direct answer
Long-term earnings growth for pharmaceutical leaders via expanded indications and delivery methods. — bullish pressure on LLY via TAM expansion for Zepbound/Mounjaro.
- Original publisher
- Market Ontology
- Evidence through
- 2026-06-17
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “GLP-1 Market Projected to Reach $95.3B by 2035”, revision 1, evidence through 2026-06-17. https://marketontology.com/catalysts/2026-06-17/glp-1-market-projected-to-reach-95-3b-by-2035-5e7938
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| LLY | ▲Bull | 1–3 months | TAM expansion for Zepbound/Mounjaro | 75 |
| NVO | ▲Bull | 1–3 months | TAM expansion for Wegovy/Ozempic | 71 |
GLP-1 Market Projected to Reach $95.3B by 2035
Long-term earnings growth for pharmaceutical leaders via expanded indications and delivery methods. — bullish pressure on LLY via TAM expansion for Zepbound/Mounjaro.
Projected 12.1% CAGR for GLP-1 market.
- SourceProjected 12.1% CAGR for GLP-1 market.
- TransmissionLong-term earnings growth for pharmaceutical leaders via expanded indications and delivery methods.
- SummaryThe GLP-1 sector remains a primary growth engine for big pharma. Oral formulations are expected to significantly increase patient adoption. Eli Lilly and Novo Nordisk maintain a dominant competitive position.
- LLYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- LLY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- LLY price vs. pre-event level
- LLY volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
GLP-1 Market Projected to Reach $95.3B by 2035
Long-term earnings growth for pharmaceutical leaders via expanded indications and delivery methods. — bullish pressure on NVO via TAM expansion for Wegovy/Ozempic.
Projected 12.1% CAGR for GLP-1 market.
- SourceProjected 12.1% CAGR for GLP-1 market.
- TransmissionLong-term earnings growth for pharmaceutical leaders via expanded indications and delivery methods.
- SummaryThe GLP-1 sector remains a primary growth engine for big pharma. Oral formulations are expected to significantly increase patient adoption. Eli Lilly and Novo Nordisk maintain a dominant competitive position.
- NVODirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- NVO closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- NVO price vs. pre-event level
- NVO volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| NVO | Bullishagreed | 43.52 2026-06-17 | -0.76% | +9.47% | +15.63% |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity trials through 2028LLY NVO VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 TrialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity pipeline trialsLLY VKTX
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Viking financing keeps obesity trial runway open through 2028LLY VKTX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.